Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for osteoporosis
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Evidence-based prevention and treatment of osteoporosis after spinal cord injury: a systematic review. Spinal cord injury (SCI) results in accelerated bone mineral density (BMD) loss and disorganization of trabecular bone architecture. The mechanisms underlying post-SCI osteoporosis are complex and different from other types of osteoporosis. Findings of studies investigating efficacy of pharmacological or rehabilitative interventions in SCI-related osteoporosis are controversial. The aim (...) of this study was to review the literature pertaining to prevention and evidence-based treatments of SCI-related osteoporosis.In this systematic review, MEDLINE, EMBASE, PubMed, and the Cochrane Library were used to identify papers from 1946 to December 31, 2015. The search strategy involved the following keywords: spinal cord injury, osteoporosis, and bone loss.Finally, 56 studies were included according to the inclusion criteria. Only 16 randomized controlled trials (involving 368 patients) were found. We
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update from the American College of Physicians. This guideline updates the 2008 American College of Physicians (ACP) recommendations on treatment of low bone density and osteoporosis to prevent fractures in men and women. This guideline is endorsed by the American Academy of Family Physicians.The ACP Clinical Guidelines Committee based these recommendations on a systematic review (...) and vertebral fractures in women who have known osteoporosis. (Grade: strong recommendation; high-quality evidence).ACP recommends that clinicians treat osteoporotic women with pharmacologic therapy for 5 years. (Grade: weak recommendation; low-quality evidence).ACP recommends that clinicians offer pharmacologic treatment with bisphosphonates to reduce the risk for vertebral fracture in men who have clinically recognized osteoporosis. (Grade: weak recommendation; low-quality evidence).ACP recommends against
Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis. Complications of chronic kidney disease (CKD) include weak bones and increased fracture risk.To review the benefits and harms of osteoporosis medications (bisphosphonates, teriparatide, raloxifene, and denosumab) compared with placebo, usual care, or active control in terms of bone mineral density (BMD), fractures, and safety in patients with CKD.PubMed and the Cochrane (...) Central Register of Controlled Trials from December 2006 through December 2016.Paired reviewers independently screened abstracts and full-text articles for English-language, randomized, controlled trials that had at least 6 months of follow-up; evaluated osteoporosis medications among patients with CKD; and reported on BMD, fractures, or safety (mortality and adverse events).Two reviewers serially abstracted data and independently assessed risk of bias and graded the strength of evidence (SOE
Teriparatide (Movymia) - osteoporosis 10 November 2016 EMA/88527/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report Movymia International non-proprietary name: teriparatide Procedure No. EMEA/H/C/004368/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 (...) authorisation to the European Medicines Agency (EMA) for Movymia, through the centralised procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 726/2004. The applicant applied for the following indication: Movymia is indicated in adults. Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and nonvertebral fractures but not hip fractures has been demonstrated
Answer to the Letter to the Editor of He Maolin et al. concerning "Comparison of unilateral versus bilateral percutaneous kyphoplasty for the treatment of patients with osteoporosis vertebral compression fracture (OVCF): a systematic review and meta-analy 28168337 2018 04 02 2018 12 02 1432-0932 26 4 2017 04 European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society Eur Spine (...) J Answer to the Letter to the Editor of He Maolin et al. concerning "Comparison of unilateral versus bilateral percutaneous kyphoplasty for the treatment of patients with osteoporosis vertebral compression fracture (OVCF): a systematic review and meta-analysis" by Cheng X, Long HQ, Xu JH, et al. Eur Spine J (2016) 25: 3439. doi:10.1007/s00586-016-4395-6. 1322-1323 10.1007/s00586-017-4965-2 Cheng Xing X Department of Spine Surgery, The First Affiliated Hospital of Sun Yat-sen University
Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a DMP "osteoporosis" 1 Translation of Chapters 1 to 6 of the final report Systematische Leitlinienrecherche und -bewertung sowie Extraktion relevanter Empfehlungen für ein DMP Osteoporose (Version 1.0; Status: 1 April 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally (...) binding. Extract Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a DMP “osteoporosis” 1 IQWiG Reports – V14-03 Extract of final report V14-03 Version 1.0 Guideline search and appraisal for a DMP “osteoporosis” 1 April 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Systematic guideline search and appraisal, as well as extraction of relevant
Letter to the Editor concerning "Comparison of unilateral versus bilateral percutaneous kyphoplasty for the treatment of patients with osteoporosis vertebral compression fracture (OVCF): a systematic review and meta-analysis" by X. Cheng et al. Eur Spine 28138778 2018 04 02 2018 12 02 1432-0932 26 4 2017 04 European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society Eur Spine (...) J Letter to the Editor concerning "Comparison of unilateral versus bilateral percutaneous kyphoplasty for the treatment of patients with osteoporosis vertebral compression fracture (OVCF): a systematic review and meta-analysis" by X. Cheng et al. Eur Spine J (2016); doi:10.1007/s00586-016-4395-6. 1320-1321 10.1007/s00586-017-4954-5 Gao Shangzhi S Division of Spinal Surgery, The First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Rd, Nanning, Guangxi, 530021, China. He
Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy. Corticosteroid treatment is considered the 'gold standard' for Duchenne muscular dystrophy (DMD); however, it is also known to induce osteoporosis and thus increase the risk of vertebral fragility fractures. Good practice in the care of those with DMD requires prevention of these adverse effects. Treatments to increase bone mineral density include (...) bisphosphonates and vitamin D and calcium supplements, and in adolescents with pubertal delay, testosterone. Bone health management is an important part of lifelong care for patients with DMD.To assess the effects of interventions to prevent or treat osteoporosis in children and adults with DMD taking long-term corticosteroids; to assess the effects of these interventions on the frequency of vertebral fragility fractures and long-bone fractures, and on quality of life; and to assess adverse events.On 12
Diagnosis and treatment of osteoporosis. Diagnosis and treatment of osteoporosis. | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100% composed of volunteers and interested (...) * Remember Me Don't have an account? The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018 because federal funding through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our . Guideline Summary NGC:011292 2017 Jul NEATS Assessment Diagnosis and treatment of osteoporosis. Allen S, Forney-Gorman A, Homan M, Kearns A, Kramlinger A, Sauer M. Diagnosis and treatment of osteoporosis. Bloomington
Treatment of Low Bone Density or Osteoporosis Treatment of Low Bone Density or Osteoporosis -- Clinical Recommendation Welcome Search Search Specify your search AAFP.org Patient Care Clinical Practice Guideline Treatment of Low Bone Density or Osteoporosis Treatment of Low Bone Density or Osteoporosis (Endorsed, April 2017) The guideline, Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women , was developed by the American College of Physicians and was endorsed (...) by the American Academy of Family Physicians. Key Recommendations Pharmacologic treatment with alendronate, risedronate, zoledronic acid, or denosumab should be prescribed for women with osteoporosis to reduce the risk of hip and vertebral fractures. Pharmacologic treatment should continue for five years, during which time bone density monitoring should not be done. Menopausal estrogen therapy, menopausal estrogen plus progesterone, or raloxifene should not be used in women with osteoporosis. The decision
American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis ARTHRITIS & RHEUMATOLOGY Vol. 69, No. 8, August 2017, pp 1521–1537 DOI 10.1002/art.40137 V C 2017, American College of Rheumatology SPECIAL ARTICLE 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis Lenore Buckley, 1 Gordon Guyatt, 2 Howard A. Fink, 3 Michael Cannon, 4 Jennifer Grossman, 5 Karen E. Hansen, 6 Mary (...) . Results. Because of limited evidence regarding the benefits and harms of interventions in GC users, most recommendationsinthisguideline areconditional (uncertain balance between benefits and harms). Rec- ommendations include treating only with calcium and vitamin D in adults at low fracture risk, treating with calcium and vitamin D plus an additional osteoporosis medication(oralbisphosphonatepreferred)inadultsat moderate-to-high fracturerisk,continuing calcium plus
Diagnosis and Treatment of OsteoporosisOsteoporosis, Diagnosis and Treatment of | ICSI The MN Health Collaborative includes physicians and other representatives from major healthcare organizations working together to address major health topics affecting Minnesota communities today. ICSI has been developing evidence-based clinical practice guidelines to improve patient care since 1993. ICSI helps forward-focused Minnesota health organizations find ways to redefine and redesign systems (...) and the market. Together, we aim to improve care and reduce costs for our patients, families and communities. e Guidelines Osteoporosis, Diagnosis and Treatment of REVISION DATE: JULY 2017 / NINTH EDITION GUIDELINE SUMMARY This guideline is targeted toward identification and treatment of adult patients with osteopenia and osteoporosis. This includes a detailed discussion of risk factors for bone loss and primary prevention with all patients presenting for routine health visits. It also addresses
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update from the American College of Physicians Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women | Annals of Internal Medicine | American College of Physicians '); } Sign in below to access your subscription for full content INDIVIDUAL SIGN IN | You will be directed to acponline.org to register and create your Annals account INSTITUTIONAL SIGN (...) IN | | Subscribe to Annals of Internal Medicine . You will be directed to acponline.org to complete your purchase. Search Clinical Guidelines | 6 June 2017 Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians Free Amir Qaseem, MD, PhD, MHA; Mary Ann Forciea, MD; Robert M. McLean, MD; Thomas D. Denberg, MD, PhD; for the Clinical Guidelines Committee of the American College of Physicians Amir Qaseem, MD
An overview and management of osteoporosisOsteoporosis -related to various factors including menopause and aging- is the most common chronic metabolic bone disease, which is characterized by increased bone fragility. Although it is seen in all age groups, gender, and races, it is more common in Caucasians (white race), older people, and women. With an aging population and longer life span, osteoporosis is increasingly becoming a global epidemic. Currently, it has been estimated that more than (...) 200 million people are suffering from osteoporosis. According to recent statistics from the International Osteoporosis Foundation, worldwide, 1 in 3 women over the age of 50 years and 1 in 5 men will experience osteoporotic fractures in their lifetime. Every fracture is a sign of another impending one. Osteoporosis has no clinical manifestations until there is a fracture. Fractures cause important morbidity; in men, in particular, they can cause mortality. Moreover, osteoporosis results
Cost-Effectiveness of Zoledronic Acid to Prevent and Treat Postmenopausal Osteoporosis in Comparison with Routine Medical Treatment Fractures caused by osteoporosis are prevalent among elderly females, which reduce quality of life significantly. This study aimed at comparing cost-effectiveness of Zoledronic acid in preventing and treating post-menopause osteoporosis as compared with routine medical treatment.This cost-effectiveness study was carried out retrospectively from the Ministry (...) fracture for a 36-month period were about 0.82, 0.57, and 1.06, respectively. Vertebral and hip fractures, and non-vertebral fractures or any clinical fracture for a 12-month period were calculated as 1.14 and 0.64, respectively. In other words, Zoledronic acid consumption approach is a cheaper and better approach based on an economic assessment, and it can be considered as a dominant approach.According to the cost-effectiveness of zoledronic acid in the prevention and treatment of osteoporosis